Form 4: Fulcrum Therapeutics Director Robert J. Gould Reports Stock Option Grant

Director Robert J. Gould reports the acquisition of stock options for 30,000 shares of Fulcrum Therapeutics common stock.

Summary

• Robert J. Gould, a director of Fulcrum Therapeutics, Inc. (FULC), reported a transaction on June 17, 2024.
• Gould acquired stock options for 30,000 shares of common stock.
• The exercise price of the options is $7.
• The options vest on the first anniversary of the grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
• The options expire on June 16, 2034.
• Following the transaction, Gould directly owns options for 30,000 shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of aligning management with shareholder interests, but it's not a major event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates